Drug Trial Radar · NCT04163185
Initiating Early Control of Migraine Pain and Associated Symptoms
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
302
Actual
Start
Oct 8, 2019
Primary completion
Mar 16, 2020
Study completion Mar 23, 2020
Sponsor
- Lead sponsor
- Axsome Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults. AXS-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. This study is designed to evaluate the efficacy and safety of AXS-07 compared to placebo. This is a randomized, double-blind, single-dose, placebo-controlled trial. Subjects who successfully complete the screening period and continue to meet all entry criteria will be randomly assigned to take one dose of either AXS-07 or placebo upon the earliest onset of migraine pain.
Conditions
- Migraine
Interventions
AXS-07 (MoSEIC meloxicam and rizatriptan)Drug
AXS-07 tablet taken once upon the earliest onset of migraine pain.
PlaceboDrug
Placebo tablet taken once upon the earliest onset of migraine pain.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Achieving Headache Pain Freedom at Hour 2Time frame: Hour 2
- Percentage of Subjects With Absence of Most Bothersome Symptom at Hour 2Time frame: Hour 2
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Site
Birmingham, Alabama
Clinical Research Site
Birmingham, Alabama
Clinical Research Site
Mobile, Alabama
Clinical Research Site
Colton, California
Clinical Research Site
Encino, California
Clinical Research Site
Los Alamitos, California
Clinical Research Site
Los Angeles, California
Clinical Research Site
Redlands, California
Clinical Research Site
Santa Monica, California
Clinical Research Site
Spring Valley, California
Clinical Research Site
Walnut Creek, California
Clinical Research Site
Hallandale, Florida
Clinical Research Site
Jacksonville, Florida
Clinical Research Site
Lake City, Florida
Clinical Research Site
Lake Worth, Florida
Clinical Research Site
Ocoee, Florida
Clinical Research Site
Orlando, Florida
Clinical Research Site
Ormond Beach, Florida
Clinical Research Site
South Miami, Florida
Clinical Research Site
Sunrise, Florida
Clinical Research Site
Tampa, Florida
Clinical Research Site
Stockbridge, Georgia
Clinical Research Site
Evanston, Illinois
Clinical Research Site
Louisville, Kentucky
Clinical Research Site
Boston, Massachusetts
Clinical Research Site
Waltham, Massachusetts
Clinical Research Site
Ann Arbor, Michigan
Clinical Research Site
Springfield, Missouri
Clinical Research Site
Albuquerque, New Mexico
Clinical Research Site
Manlius, New York
Clinical Research Site
Williamsville, New York
Clinical Research Site
High Point, North Carolina
Clinical Research Site
Oklahoma City, Oklahoma
Clinical Research Site
Philadelphia, Pennsylvania
Clinical Research Site
Charleston, South Carolina
Clinical Research Site
Mt. Pleasant, South Carolina
Clinical Research Site
Memphis, Tennessee
Clinical Research Site
Nashville, Tennessee
Clinical Research Site
Austin, Texas
Clinical Research Site
Salt Lake City, Utah
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.